Matching-adjusted indirect treatment comparison of ribociclib and palbociclib in HR+, HER2− advanced breast cancer

Matching-adjusted indirect treatment comparison of ribociclib and palbociclib in HR+, HER2− advanced breast cancer

Gabriel Tremblay,1 David Chandiwana,2 Mike Dolph,1 Jaclyn Hearnden,1 Anna Forsythe,1 Mauricio Monaco2 1Purple Squirrel Economics, New York, NY, USA; 2Novartis Pharmaceutical Corporation, East Hanover, NJ, USA Background: Ribociclib (RIBO) and palbociclib (PALBO), combined with letrozole (LET), have...

Full description

Bibliographic Details
Main Authors: Tremblay G, Chandiwana D, Dolph M, Hearnden J, Forsythe A, Monaco M
Format: Article
Language:English
Published: Dove Medical Press 2018-05-01
Series:Cancer Management and Research
Subjects:
breast cancer
indirect treatment comparison
matching-adjusted indirect treatment comparison
ribociclib
palbociclib
Online Access:https://www.dovepress.com/matching-adjusted-indirect-treatment-comparison-of-ribociclib-and-palb-peer-reviewed-article-CMAR

Internet

https://www.dovepress.com/matching-adjusted-indirect-treatment-comparison-of-ribociclib-and-palb-peer-reviewed-article-CMAR

Similar Items